Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A1 | P60842 | 8/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | EDNRB | P24530 | 1/20 | 0.32 |
| ▸ | EDNRA | P25101 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009527 | 0.97 | LMNA (0.35) | EIF4A1TTRLMNAALDH1A1L3MBTL1 | |
| SCHEMBL1010281 | 0.94 | RARA (0.38) | EIF4A1CYP3A4HIF1A | |
| SCHEMBL1009900 | 0.93 | SIRT1 (0.34) | TTRLMNASIRT1 | |
| SCHEMBL1010912 | 0.91 | KMT2A (0.39) | EIF4A1CYP3A4ALDH1A1CYP2C19L3MBTL1 | |
| SCHEMBL15318062 | 0.91 | ALK (0.36) | LMNACSNK2A2CSNK2A1L3MBTL1 | |
| SCHEMBL25844440 | 0.89 | MAPT (0.33) | EIF4A1EDNRBEDNRA | |
| SCHEMBL1046559 | 0.89 | MEN1 (0.32) | EIF4A1LMNACYP3A4ALDH1A1HIF1A | |
| SCHEMBL29453311 | 0.89 | MEN1 (0.32) | EIF4A1LMNACYP3A4ALDH1A1HIF1A | |
| SCHEMBL25605494 | 0.88 | SYK (0.32) | — | |
| SCHEMBL1009484 | 0.88 | HIF1A (0.38) | LMNAALDH1A1HIF1AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1872173-B9 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL INC (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-1872173-B1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL INC (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090072206-A1 | OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS | JOHNSON & JOHNSON VISION CARE, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090032782-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| EP-1869140-A1 | OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS | Johnson and Johnson Vision Care, Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006110513-A1 | OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060226402-A1 | Ophthalmic devices comprising photochromic materials having extended PI-conjugated systems | KIM BEON-KYU | 2006-10-12 | — | — | US | disclosed |
| US-20060228557-A1 | Photochromic materials having extended pi-conjugated systems and compositions and articles including the same | TRANSITIONS OPTICAL, INC. | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060228557-A1 | Photochromic materials having extended pi-conjugated systems and compositions and articles including the same | INCENP, PCNA, INTS6 | EIF4A1 1326/4885TTR 761/4885LMNA 404/4885 |
| US-20090032782-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | INTS6, INCENP, PCNA | EIF4A1 1632/4885TTR 936/4885LMNA 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.